{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:05:50Z","timestamp":1786133150056,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>\n                    The complement system is essential for host defense, but uncontrolled complement system activation leads to severe, mostly renal pathologies, such as atypical hemolytic uremic syndrome or C3 glomerulopathy. Here, we investigated a novel combinational approach to modulate complement activation by targeting C3 and the terminal pathway simultaneously. The synthetic fusion protein MFHR1 links the regulatory domains of complement factor H (FH) with the C5 convertase\/C5b-9 inhibitory fragment of the FH-related protein 1.\n                    <jats:italic toggle=\"yes\">In vitro<\/jats:italic>\n                    , MFHR1 showed cofactor and decay acceleration activity and inhibited C5 convertase activation and C5b-9 assembly, which prevented C3b deposition and reduced C3a\/C5a and C5b-9 generation. Furthermore, this fusion protein showed the ability to escape deregulation by FH-related proteins and form multimeric complexes with increased inhibitory activity. In addition to substantially inhibiting alternative and classic pathway activation, MFHR1 blocked hemolysis mediated by serum from a patient with aHUS expressing truncated FH. In\n                    <jats:italic toggle=\"yes\">FH\u2212\/\u2212<\/jats:italic>\n                    mice, MFHR1 administration augmented serum C3 levels, reduced abnormal glomerular C3 deposition, and ameliorated C3 glomerulopathy. Taking the unique design of MFHR1 into account, we suggest that the combination of proximal and terminal cascade inhibition together with the ability to form multimeric complexes explain the strong inhibitory capacity of MFHR1, which offers a novel basis for complement therapeutics.\n                  <\/jats:p>","DOI":"10.1681\/asn.2017070738","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T12:45:29Z","timestamp":1516020329000},"page":"1141-1153","source":"Crossref","is-referenced-by-count":36,"title":["The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential"],"prefix":"10.1681","volume":"29","author":[{"given":"Stefan","family":"Michelfelder","sequence":"first","affiliation":[{"name":"Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center, Faculty of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedericke","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center, Faculty of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"W\u00e4ldin","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center, Faculty of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim V.","family":"H\u00f6rle","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center, Faculty of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pohl","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center, Faculty of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Parsons","sequence":"additional","affiliation":[{"name":"Plant Biotechnology, Faculty of Biology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5496-6711","authenticated-orcid":false,"given":"Ralf","family":"Reski","sequence":"additional","affiliation":[{"name":"Plant Biotechnology, Faculty of Biology, and"},{"name":"Centre for Biological Signaling Studies, University of Freiburg, Freiburg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva L.","family":"Decker","sequence":"additional","affiliation":[{"name":"Plant Biotechnology, Faculty of Biology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Zipfel","sequence":"additional","affiliation":[{"name":"Leibniz Institute for Natural Product Research and Infection Biology, Friedrich Schiller University, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Skerka","sequence":"additional","affiliation":[{"name":"Leibniz Institute for Natural Product Research and Infection Biology, Friedrich Schiller University, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"H\u00e4ffner","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics, Adolescent Medicine and Neonatology, Medical Center, Faculty of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,1,15]]},"reference":[{"key":"B1-20231016","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4049\/jimmunol.155.1.348","article-title":"Identification of complement regulatory domains in human factor H.","volume":"155","author":"Gordon","year":"1995","journal-title":"J Immunol"},{"key":"B2-20231016","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1073\/pnas.73.9.3268","article-title":"Control of the amplification convertase of complement by the plasma protein beta1H.","volume":"73","author":"Weiler","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B3-20231016","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.molimm.2013.06.001","article-title":"Complement factor H related proteins (CFHRs).","volume":"56","author":"Skerka","year":"2013","journal-title":"Mol Immunol"},{"key":"B4-20231016","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1182\/blood-2009-02-205641","article-title":"Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation.","volume":"114","author":"Heinen","year":"2009","journal-title":"Blood"},{"key":"B5-20231016","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1093\/hmg\/ddq399","article-title":"An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD).","volume":"19","author":"Fritsche","year":"2010","journal-title":"Hum Mol Genet"},{"key":"B6-20231016","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1073\/pnas.1219260110","article-title":"Dimerization of complement factor H-related proteins modulates complement activation in vivo.","volume":"110","author":"Goicoechea de Jorge","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B7-20231016","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1586\/17474086.2014.953926","article-title":"Complement in paroxysmal nocturnal hemoglobinuria: Exploiting our current knowledge to improve the treatment landscape.","volume":"7","author":"Mastellos","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"B8-20231016","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ndt\/gfu317","article-title":"Update on C3 glomerulopathy.","volume":"31","author":"Barbour","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B9-20231016","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: Core curriculum 2015.","volume":"66","author":"Noris","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B10-20231016","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases.","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B11-20231016","doi-asserted-by":"crossref","first-page":"28445","DOI":"10.1038\/srep28445","article-title":"A previously unrecognized role of C3a in proteinuric progressive nephropathy.","volume":"6","author":"Morigi","year":"2016","journal-title":"Sci Rep"},{"key":"B12-20231016","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1681\/ASN.2013050450","article-title":"Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.","volume":"25","author":"Locatelli","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B13-20231016","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ki.2013.134","article-title":"Novel roles of complement in renal diseases and their therapeutic consequences.","volume":"84","author":"Wada","year":"2013","journal-title":"Kidney Int"},{"key":"B14-20231016","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40261-015-0300-z","article-title":"Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.","volume":"35","author":"Riedl","year":"2015","journal-title":"Clin Drug Investig"},{"key":"B15-20231016","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B16-20231016","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2147\/TCRM.S96720","article-title":"Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: Patient selection and special considerations.","volume":"12","author":"Al-Ani","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"B17-20231016","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: Mechanistic evidence for residual C5 activity during strong complement activation.","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"key":"B18-20231016","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00467-015-3078-6","article-title":"A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.","volume":"30","author":"Schalk","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"B19-20231016","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis.","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B20-20231016","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2015-02-625871","article-title":"Complement C3dg-mediated erythrophagocytosis: Implications for paroxysmal nocturnal hemoglobinuria.","volume":"126","author":"Lin","year":"2015","journal-title":"Blood"},{"key":"B21-20231016","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab.","volume":"370","author":"Nishimura","year":"2014","journal-title":"N Engl J Med"},{"key":"B22-20231016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4614-4118-2_1","article-title":"Progress and trends in complement therapeutics.","volume":"735","author":"Ricklin","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"B23-20231016","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/eci.12419","article-title":"Compstatin: A C3-targeted complement inhibitor reaching its prime for bedside intervention.","volume":"45","author":"Mastellos","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"B24-20231016","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.imbio.2015.06.012","article-title":"Therapeutic control of complement activation at the level of the central component C3.","volume":"221","author":"Ricklin","year":"2016","journal-title":"Immunobiology"},{"key":"B25-20231016","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1053\/j.ajkd.2004.10.018","article-title":"Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.","volume":"45","author":"Licht","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B26-20231016","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.ki.5000269","article-title":"Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).","volume":"70","author":"Licht","year":"2006","journal-title":"Kidney Int"},{"key":"B27-20231016","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00467-015-3111-9","article-title":"Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.","volume":"30","author":"H\u00e4ffner","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"B28-20231016","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1681\/ASN.2015070745","article-title":"Moss-produced, glycosylation-optimized human factor H for therapeutic application in complement disorders.","volume":"28","author":"Michelfelder","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B29-20231016","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.4049\/jimmunol.1203548","article-title":"Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.","volume":"190","author":"Schmidt","year":"2013","journal-title":"J Immunol"},{"key":"B30-20231016","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4049\/jimmunol.1300269","article-title":"An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H.","volume":"191","author":"Hebecker","year":"2013","journal-title":"J Immunol"},{"key":"B31-20231016","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/ki.2015.233","article-title":"An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.","volume":"88","author":"Nichols","year":"2015","journal-title":"Kidney Int"},{"key":"B32-20231016","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1681\/ASN.2013010045","article-title":"Soluble CR1 therapy improves complement regulation in C3 glomerulopathy.","volume":"24","author":"Zhang","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B33-20231016","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood-2011-06-359646","article-title":"Design and development of TT30, a novel C3d-targeted C3\/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.","volume":"118","author":"Fridkis-Hareli","year":"2011","journal-title":"Blood"},{"key":"B34-20231016","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1681\/ASN.2014121195","article-title":"Efficacy of targeted complement inhibition in experimental C3 glomerulopathy.","volume":"27","author":"Ruseva","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"2 Pt A","key":"B35-20231016","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molimm.2015.01.028","article-title":"Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.","volume":"67","author":"Melis","year":"2015","journal-title":"Mol Immunol"},{"key":"B36-20231016","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1517\/17460441.2.6.799","article-title":"How to design multi-target drugs.","volume":"2","author":"Korcsm\u00e1ros","year":"2007","journal-title":"Expert Opin Drug Discov"},{"key":"B37-20231016","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2249.2006.03071.x","article-title":"The C-terminus of complement regulator Factor H mediates target recognition: Evidence for a compact conformation of the native protein.","volume":"144","author":"Oppermann","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"B38-20231016","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nsmb.3196","article-title":"Structural basis for therapeutic inhibition of complement C5.","volume":"23","author":"Jore","year":"2016","journal-title":"Nat Struct Mol Biol"},{"key":"B39-20231016","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00467-003-1192-3","article-title":"Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality.","volume":"18","author":"Gerber","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"B40-20231016","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.0601094103","article-title":"Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice.","volume":"103","author":"Pickering","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B41-20231016","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ng912","article-title":"Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H.","volume":"31","author":"Pickering","year":"2002","journal-title":"Nat Genet"},{"key":"B42-20231016","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4049\/jimmunol.1501919","article-title":"Comparative analysis of novel complement-targeted inhibitors, miniFH, and the natural regulators factor H and factor H-like protein 1 reveal functional determinants of complement regulation.","volume":"196","author":"Harder","year":"2016","journal-title":"J Immunol"},{"key":"B43-20231016","doi-asserted-by":"crossref","first-page":"e0166200","DOI":"10.1371\/journal.pone.0166200","article-title":"Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b\/C3d interactions.","volume":"11","author":"Hannan","year":"2016","journal-title":"PLoS One"},{"key":"B44-20231016","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1172\/JCI71866","article-title":"Complement factor H-related hybrid protein deregulates complement in dense deposit disease.","volume":"124","author":"Chen","year":"2014","journal-title":"J Clin Invest"},{"key":"B45-20231016","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1172\/JCI68280","article-title":"C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.","volume":"123","author":"Tortajada","year":"2013","journal-title":"J Clin Invest"},{"key":"B46-20231016","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0140-6736(10)60670-8","article-title":"Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.","volume":"376","author":"Gale","year":"2010","journal-title":"Lancet"},{"key":"B47-20231016","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.it.2015.04.008","article-title":"Factor H-related proteins determine complement-activating surfaces.","volume":"36","author":"J\u00f3zsi","year":"2015","journal-title":"Trends Immunol"},{"key":"B48-20231016","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.4049\/jimmunol.155.12.5663","article-title":"Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1.","volume":"155","author":"K\u00fchn","year":"1995","journal-title":"J Immunol"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201804000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:29:25Z","timestamp":1786130965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201804000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,15]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2017070738","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,15]]}}}